dolutegravir; lamivudine; tenofovir disoproxil fumarate
DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE (dolutegravir; lamivudine; tenofovir disoproxil fumarate) by Shanghai Sunway Biotech is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
This is a fixed-dose combination oral tablet containing dolutegravir, lamivudine, and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults and children weighing at least 6 kg. The combination works by inhibiting HIV-1 reverse transcriptase and integrase, suppressing viral replication through multiple mechanisms of action. This triple-agent regimen represents a potent antiretroviral strategy suitable for treatment-naive and experienced patients.
As a pre-launch product from Shanghai Sunway Biotech, positions offer early-stage commercial development experience in a crowded HIV FDC market with significant growth potential in emerging markets.
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Worked on DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE at Shanghai Sunway Biotech? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on this pre-launch product offers early career exposure to emerging market HIV therapy commercialization, with emphasis on pricing, reimbursement strategy, and competitive positioning rather than clinical development. The crowded competitive landscape demands expertise in market access, generic competition management, and efficient launch execution.